Neubase Therapeutics Stock Short Ratio
| NBSE Stock | USD 0.42 0.02 4.55% |
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
NeuBase | Short Ratio |
NeuBase Therapeutics Company Short Ratio Analysis
NeuBase Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current NeuBase Therapeutics Short Ratio | 0.60 X |
Most of NeuBase Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeuBase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NeuBase Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for NeuBase Therapeutics is extremely important. It helps to project a fair market value of NeuBase Stock properly, considering its historical fundamentals such as Short Ratio. Since NeuBase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NeuBase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NeuBase Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
NeuBase Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, NeuBase Therapeutics has a Short Ratio of 0.6 times. This is 84.62% lower than that of the Biotechnology sector and 91.9% lower than that of the Health Care industry. The short ratio for all United States stocks is 85.0% higher than that of the company.
NeuBase Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeuBase Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics of similar companies.NeuBase Therapeutics is currently under evaluation in short ratio category among related companies.
NeuBase Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in NeuBase Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of NeuBase Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing NeuBase Therapeutics' value.| Shares | Tower Research Capital Llc | 2023-12-31 | 2.4 K | Bank Of America Corp | 2023-12-31 | 804 | First Manhattan Co. Llc | 2023-12-31 | 353 | Royal Bank Of Canada | 2023-12-31 | 300 | Blackrock Inc | 2023-12-31 | 84.0 | Wells Fargo & Co | 2023-12-31 | 79.0 | Advisor Group Holdings, Inc. | 2023-12-31 | 22.0 | Pnc Financial Services Group Inc | 2023-12-31 | 21.0 | Global Wealth Management Investment Advisory, Inc. | 2023-12-31 | 12.0 | Greenlight Capital, Inc | 2023-12-31 | 136.3 K | Ubs Group Ag | 2023-12-31 | 65.7 K |
NeuBase Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (5.6 M) | ||||
| Shares Outstanding | 3.75 M | ||||
| Shares Owned By Insiders | 13.37 % | ||||
| Shares Owned By Institutions | 12.68 % | ||||
| Number Of Shares Shorted | 149.12 K | ||||
| Price To Earning | (4.17) X | ||||
| Price To Book | 0.18 X | ||||
| EBITDA | (32.49 M) | ||||
| Net Income | (33.78 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 6 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 2.45 X | ||||
| Cash Flow From Operations | (29.01 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (18.60) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 140.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.96 | ||||
| Market Capitalization | 1.65 M | ||||
| Total Asset | 32.69 M | ||||
| Retained Earnings | (102.74 M) | ||||
| Working Capital | 20.48 M | ||||
| Current Asset | 4.14 M | ||||
| Current Liabilities | 1.6 M | ||||
| Net Asset | 32.69 M |
About NeuBase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out NeuBase Therapeutics Piotroski F Score and NeuBase Therapeutics Altman Z Score analysis. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.